Drug Trial Radar · NCT04879420
Replication of the VERO Osteoporosis Trial in Healthcare Claims Data
Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12,757
Actual
Start
Oct 29, 2020
Primary completion
Jun 11, 2021
Study completion Jun 11, 2021
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 10, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 45 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
- Osteoporosis
Interventions
TeriparatideDrug
Teriparatide dispensing claim is used as the reference group.
RisedronateDrug
Risedronate dispensing claim is used as the exposure group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- New vertebral fracturesTime frame: Through study completion (earliest of 730 days or censoring)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.